This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sader, H. S.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sader, H. S.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3501-3512, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3501-3512.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Helio S. Sader,1,2* Thomas R. Fritsche,1 Koné Kaniga,3 Yigong Ge,3 and Ronald N. Jones1,4

JMI Laboratories, North Liberty, Iowa,1 Universidade Federal de São Paulo, São Paulo, Brazil,2 Peninsula Pharmaceuticals, Alameda, California,3 Tufts University School of Medicine, Boston, Massachusetts4

Received 8 February 2005/ Returned for modification 29 March 2005/ Accepted 15 May 2005

PPI-0903M is a novel N-phosphono-type cephalosporin active against oxacillin-resistant staphylococci and many other gram-positive organisms. This study evaluated the in vitro activity and spectrum of PPI-0903M against 1,478 recent clinical isolates collected from 80 medical centers (22 countries). PPI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against gram-negative pathogens.

* Corresponding author. Mailing address: JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: helio-sader{at}jmilabs.com.

Antimicrobial Agents and Chemotherapy, August 2005, p. 3501-3512, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3501-3512.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Vidaillac, C., Leonard, S. N., Sader, H. S., Jones, R. N., Rybak, M. J. (2009). In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including {beta}-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 2360-2366 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2009). In Vitro Antimicrobial Activity of a New Cephalosporin, Ceftaroline, and Determination of Quality Control Ranges for MIC Testing. Antimicrob. Agents Chemother. 53: 1271-1274 [Abstract] [Full Text]  
  • McGee, L., Biek, D., Ge, Y., Klugman, M., du Plessis, M., Smith, A. M., Beall, B., Whitney, C. G., Klugman, K. P. (2009). In Vitro Evaluation of the Antimicrobial Activity of Ceftaroline against Cephalosporin-Resistant Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 53: 552-556 [Abstract] [Full Text]  
  • Fenoll, A., Aguilar, L., Robledo, O., Gimenez, M.-J., Granizo, J.-J., Biek, D., Tarrago, D. (2008). In Vitro Activity of Ceftaroline against Streptococcus pneumoniae Isolates Exhibiting Resistance to Penicillin, Amoxicillin, and Cefotaxime. Antimicrob. Agents Chemother. 52: 4209-4210 [Full Text]  
  • Ge, Y., Biek, D., Talbot, G. H., Sahm, D. F. (2008). In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States. Antimicrob. Agents Chemother. 52: 3398-3407 [Abstract] [Full Text]  
  • Pillar, C. M., Aranza, M. K., Shah, D., Sahm, D. F. (2008). In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J Antimicrob Chemother 61: 595-602 [Abstract] [Full Text]  
  • Sader, H. S., Fritsche, T. R., Jones, R. N. (2008). Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 1153-1155 [Abstract] [Full Text]  
  • Talbot, G. H., Thye, D., Das, A., Ge, Y. (2007). Phase 2 Study of Ceftaroline versus Standard Therapy in Treatment of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 51: 3612-3616 [Abstract] [Full Text]  
  • Jacqueline, C., Caillon, J., Le Mabecque, V., Miegeville, A.-F., Hamel, A., Bugnon, D., Ge, J. Y., Potel, G. (2007). In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 51: 3397-3400 [Abstract] [Full Text]  
  • Mushtaq, S., Warner, M., Ge, Y., Kaniga, K., Livermore, D. M. (2007). In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 60: 300-311 [Abstract] [Full Text]  
  • Jones, R. N., Fritsche, T. R., Ge, Y., Kaniga, K., Sader, H. S. (2005). Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 56: 1047-1052 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»